Introduction {#s1}
============

Osteoarthritis (OA) is the leading cause of physical disability in industrialised nations with severely impaired quality of life due to pain and loss of joint functioning.[@R1] Pain is the major symptom of knee OA, and pain and disability in the presence of radiographic knee OA are the primary indications for total knee replacement. A patient who has severe knee pain and extensive radiographic evidence of OA is thought to have an 'obvious' explanation for the pain.[@R2] Within the same patient, knee pain has been shown to be higher in the knee with greater x-ray damage.[@R3] Yet, a considerable number of individuals have advanced radiographic OA (Kellgren--Lawrence (K/L) scores ≥3) in asymptomatic joints.[@R2] [@R3] For example, in the Framingham study only 19% of people with K/L=2 and 40% of those with K/L≥3 had knee pain on most days in the previous month,[@R4] and in the Baltimore longitudinal study only 56% of cases with K/L≥3 had current pain.[@R5]

Thus, although a correlation between OA joint damage and pain can be found, there is often discordance between the degree of structural change and the severity of pain, so disease severity defined exclusively by structural degeneration is inadequate.

One possible factor influencing pain severity in the presence of joint damage is a patient\'s individual sensitivity to pain, which has been shown to be strongly influenced by genetics.[@R6] The transient receptor potential cation channel, subfamily V, member 1 (*TRPV1*) is a thermosensitive channel present in a subpopulation of primary afferent sensory neurons and activated by noxious heat.[@R7] [@R8] Notably, inflammatory stimuli sensitise *TRPV1*, a process that contributes to pain hypersensitivity in the context of tissue injury (see references in the article by Huang *et al* [@R9]). Preclinical studies have provided mounting evidence for a contribution of *TRPV1* to pain in animal models of OA. Indeed, expression of *TRPV1* is upregulated in the cell bodies of primary afferent fibres innervating the joint in the monosodium iodoacetate model of OA pain[@R10] and systemic administration of *TRPV1* antagonists blocks hyperalgesia and mechanical allodynia in these models.[@R11] Expression of *TRPV1,* however, is not limited to neural cells but is also found in other cells in the joint, including chondrocytes, osteoclasts, osteoblasts and synovial fibroblasts,[@R12]--[@R14] and thus the potential role of *TRPV1* in OA is not limited to pain sensation.

An amino acid variant, Ile585Val encoded by rs8065080, in the *TRPV1* gene has been reported to be associated with thermal pain sensitivity,[@R15] [@R16] with the Ile--Ile genotype corresponding to lower sensitivity to cold pain. The aim of this study was to determine whether there is a role for this genotype in risk of symptomatic knee OA compared both with healthy non-OA controls and with people with asymptomatic radiographic knee OA.

The expression of *TRPV1* in human cartilage and synovium from patients undergoing arthroplasty as well as normal mouse cartilage has also been quantified to provide evidence that *TRPV1* is present in joint tissues and may play a role in the process of cartilage breakdown leading to a damaged joint.

Subjects and methods {#s2}
====================

Data from five study cohorts from the UK, a study cohort in the USA and a study cohort from Australia were used. The study protocols for each cohort were approved by the local research ethics committees or institutional review board and all study participants gave fully informed consent to participate in genetic studies. For consistency between cohorts for the current study the radiographic definition of knee OA was a K/L grade ≥2[@R17] at the tibiofemoral compartment at one or both knees. Details on each of the study cohorts, recruitment, x-ray findings and pain assessment are included in the online supplementary section and the descriptive characteristics are shown in [table 1](#T1){ref-type="table"}. Because the Nottingham Case--Control Study did not have any asymptomatic subjects and the Hertfordshire Cohort Study had very few symptomatic subjects and these two UK study cohorts had similar age ranges, data for these two studies have been pooled for all analyses.

###### 

Descriptive characteristics of study subjects

                             Cohort name                                                                    
  -------------------------- ------------- ------------ ------------ ------------ ------------ ------------ ------------
  Cohort acronym             GOAL          HCS          Nott         Chingford    TwinsUK      COS          TASOAC
  Country of origin          UK            UK           UK           UK           UK           USA          Australia
  Knee OA                                                                                                   
  Symptomatic                n=1199        n=86         n=1703       n=68         n=45         n=83         n=86
  Age (years), mean (SD)     68.4 (7.2)    65.3 (2.8)   68.7 (8.9)   65.7 (5.8)   57.5 (7.2)   65.6 (8.3)   65.0 (7.2)
  Female (%)                 46.9          44.3         55.3         100          100          66.7         58.50
  BMI (kg/m^2^), mean (SD)   31.2 (5.4)    29.7 (5.4)   29.7 (5.4)   26.7 (3.4)   27.9(4.5)    29.1 (5.1)   31.3 (6.3)
  K/L≥3 (%)                  89.7          38.6         80.8         44.1         29.0         32.9         42.6
  TKR (%)                    94.8          9.3          90.3         23.5         26.7         24           0
  *TRPV1* 585 Ile--Ile (%)   11.4          12.8         12.9         8.8          9.3          15.5         12.6
  MAF (%)                    35.1          37.2         36.9         38.2         31.4         33.8         35.1
  Asymptomatic               n=376         n=44         n=0          n=216        n=235        n=91         n=136
  Age (years), mean (SD)     69.0 (6.7)    65.2 (6.4)   N/A          65.7 (5.9)   58.1 (7.8)   64.0 (9.8)   65.8 (7.6)
  Female (%)                 43.9          31.8         N/A          100          100          54.6         43.80
  BMI (kg/m^2^), mean (SD)   28.9 (4.9)    28.4 (4.0)   N/A          26.2 (4.4)   26.7 (4.9)   26.1 (4.7)   28.1 (4.3)
  K/L≥3 (%)                  49.5          15.9         N/A          26.4         34.0         21.7         24.8
  TKR (%)                    0             0            N/A          0            0            0            0
  *TRPV1* 585 Ile--Ile (%)   14.4          11.9         N/A          11.7         17.1         17.6         18.4
  MAF (%)                    38.2          40.4         N/A          37.4         40.2         43.5         43.4
  Unaffected                 n=743         n=542        n=728        n=532        n=978        n=0          n=329
  Age years mean (SD)        62.6 (8.4)    64.8 (2.7)   66.3 (7.4)   62.9 (5.7)   52.9 (7.2)   N/A          61.8 (7.5)
  Female (%)                 49.9          50.1         57.4         100          100          N/A          47.9
  BMI (kg/m^2^) mean (SD)    27.1 (4.4)    26.2 (3.8)   26.6(3.9)    24.7 (3.6)   24.5 (4.0)   N/A          27.4 (4.4)
  *TRPV1* 585 Ile--Ile (%)   15.5          15.6         16.1         13.6         15.0         N/A          16.20
  MAF (%)                    38.5          38.5         37.8         38.1         37.8                      38.8

BMI, body mass index; K/L, Kellgren--Lawrence; MAF, minor allele frequency; TKR, total knee replacement.

Laboratory methods {#s3}
------------------

### Genotyping {#s4}

Genomic DNA was extracted from peripheral blood and DNA from the Genetics of Osteoarthrits and Lifestyle (GOAL) cohort was further whole genome amplified using standard protocols. Genotyping of the rs8065080 single nucleotide polymorphism (SNP) was carried out by Kbioscience Ltd, Hertfordshire, UK. SNPs were genotyped using the KASPar chemistry, a competitive allele-specific PCR SNP genotyping system. The polymorphism was in Hardy--Weinberg equilibrium in controls (p\>0.05) in all cohorts. Fifty-two samples were genotyped in duplicate and the concordance rate was 100%.

Gene expression experiments {#s5}
---------------------------

All procedures to obtain and work with human samples were approved by the ethical committee for clinical research at KU Leuven and patient informed consent was obtained. The informed consents preclude the analysis of the tissues for genomic analysis. Cartilage explants were obtained from patients undergoing total knee prosthesis surgery in the department of orthopaedics, University Hospitals Leuven. Pieces of cartilage were selected from visually healthy zones of the specimens. Cartilage explants from four different donors were used in triplicate cultures. Pieces were cultured in vitro in Dulbecco\'s modified Eagle\'s medium (DMEM) (Gibco, Carlsbad, California, USA) for 10 days in the presence or absence of interleukin (IL) 1 and tumour necrosis factor α (TNFα) 10 ng/ml (Peprotech, Rocky Hill New Jersey, USA). Synovial biopsy specimens were obtained from patients undergoing arthroscopy of the knee for meniscal and cartilage injury in the department of orthopaedics or from patients with chronic arthritis undergoing diagnostic needle arthroscopy (one rheumatoid arthritis, two psoriatic arthritis) in the department of rheumatology, University Hospitals Leuven. Histological or flow cytometric analysis revealed that the control synovia had no signs of chronic inflammation. Synovial fibroblasts were collected and cultured as described by Lories *et al*.[@R18] Primary cells were cultured in DMEM/10% fetal bovine serum in the presence or absence of TNFα (0.1--10 ng/ml) and human IL-1β (0.1--10 ng/ml) for 2--24 h.

Expression levels of *TRPV1* were determined by quantitative real-time PCR using commercially available Taqman primer-probes sets (Applied Biosystems) for *TRPV1* and housekeeping gene β-actin. Data were analysed with the ΔCt method relative to housekeeping gene β-actin for the synovial tissue samples and with a standardised method for independent biological replicates based on ΔΔCt with log transformation, mean centring, and autoscaling as proposed by Willems *et al*[@R19] for the in vitro experiments.

Statistical analysis {#s6}
--------------------

The association between the CC genotype at rs8065080 (Ile--Ile at *TRPV1* codon 585) and knee OA (symptomatic and asymptomatic separately or together) versus controls was assessed by comparison of the frequency of the *TRPV1* 585 Ile--Ile genotype in knee OA cases and controls in unadjusted analyses and using a logistic regression model to adjust for covariates. The ORs from all cohorts were meta-analysed using a fixed-effects model. The natural logarithm of the odds ratio and its SE were estimated independently within each study adjusted for age, gender, body mass index (BMI) and in the case of symptomatic versus symptomatic cases also for radiographic severity (the maximum for radiographic OA (ROA) cases, the presurgical grade for the index knee in total knee replacement cases). For the TwinsUK Cohort in addition the estimates were corrected for the relatedness between individuals using a mixed-effects model with a robust estimate of the SE for the β coefficient calculated by clustering over twin pairs.

Meta-analyses of data from these different cohorts were performed using R version 2.10.1 (the R Foundation for Statistical Computing <http://www.r-project.org/>). Heterogeneity was evaluated with Q statistic and I^2^. Random-effects models were not used as no heterogeneity was seen for any of the analyses (I^2^ \<10%). Pooled analyses of all cohorts were also carried out, simply grouping all data in a single analysis.

Results {#s7}
=======

The descriptive characteristics of the study cohorts including the Ile--Ile 585 genotype frequency and the number of control, symptomatic and asymptomatic knee OA cases available for each study are shown in [table 1](#T1){ref-type="table"}.

We tested, using a crude meta-analysis (ie, simply comparing genotype frequencies), whether the Ile--Ile genotype was associated with knee OA, and found that the Ile--Ile genotype at codon position 585 of the TRPV1 protein was associated with lower risk of knee OA ([table 2](#T2){ref-type="table"}). This association was stronger when only symptomatic knee OA cases were included ([table 2](#T2){ref-type="table"}) A much more modest and not significant difference was seen between asymptomatic OA cases and controls ([table 2](#T2){ref-type="table"}) but a comparison between symptomatic and asymptomatic OA gave a statistically significant result OR=0.76 (95% CI 0.59 to 0.99) p=0.0378 ([table 2](#T2){ref-type="table"}). We then carried out a pooled analysis combining all samples regardless of cohort of origin in a single analysis, but adjusting for covariates and found results to be extremely similar to those from the meta-analysis ([table 2](#T2){ref-type="table"}).

###### 

Association between the *TRPV1* 585 Ile--Ile genotype and symptomatic or asymptomatic knee osteoarthritis (OA) in a crude meta-analysis and in pooled analysis

  Groups compared                           Sample size                                       Summary OR (95% CI) (crude Mantel--Haenzsel)   p Value meta‑analysis   Heterogeneity I^2^ p(Cochran\'s Q)   Pooled analysis OR (95% CI)                            p Value pooled analysis
  ----------------------------------------- ------------------------------------------------- ---------------------------------------------- ----------------------- ------------------------------------ ------------------------------------------------------ -------------------------------------------
  Any knee OA versus controls               4368 cases, 3852 controls                         0.83 (0.73 to 0.95)                            0.0073                  *I*^*2*^ =0% p(Q)\<0.39              0.84 (0.72 to 0.98)[\*](#T2FN1){ref-type="table-fn"}   \<0.0277[\*](#T2FN1){ref-type="table-fn"}
  Symptomatic knee OA versus controls       3270 cases, 3852 controls                         0.74 (0.64 to 0.87)                            0.00022                 *I*^*2*^ =0% p(Q)\<0.66              0.76 (0.64 to 0.92)[\*](#T2FN1){ref-type="table-fn"}   \<0.0042[\*](#T2FN1){ref-type="table-fn"}
  Asymptomatic knee OA versus controls      1098 cases, 3852 controls                         0.99 (0.81 to 1.22)                            0.93                    *I*^*2*^ =0% p(Q)\<0.67              1.01 (0.78 to 1.31)[\*](#T2FN1){ref-type="table-fn"}   \<0.92[\*](#T2FN1){ref-type="table-fn"}
  Symptomatic versus asymptomatic knee OA   3270 symptomatic cases, 1098 asymptomatic cases   0.76 (0.59 to 0.99)                            0.0378                  *I*^*2*^ =0% p(Q)\<0.87              0.74 (0.55 to 0.99)[†](#T2FN2){ref-type="table-fn"}    \<0.0417[†](#T2FN2){ref-type="table-fn"}

ORs refer to the risk of individuals carrying the *TRPV1* 585 Ile--Ile compared with Val--Ile and Val--Val individuals.

Adjusted for age, sex and body mass index (BMI).

Adjusted for age, sex, BMI and Kellgren--Lawrence grade.

All estimates are also adjusted for relatedness between twins.

We further tested for association adjusting for age, sex and BMI in each of the study cohorts independently first ([table 2](#T2){ref-type="table"}) and meta-analysed them. We confirmed the association with knee OA overall ([figure 1A](#F1){ref-type="fig"}), the stronger association between symptomatic OA versus controls ([figure 1B](#F1){ref-type="fig"}) and the lack of association between asymptomatic OA and controls ([figure 1C](#F1){ref-type="fig"}).

![Forest plot showing study specific estimates for the association between the Ile--Ile *TRPV1* 585 genotype and (A) knee osteoarthritis (OA; regardless of symptoms) versus controls; (B) symptomatic knee OA versus controls; (C) asymptomatic knee OA versus controls; (D) symptomatic versus asymptomatic knee OA. \*OR estimates are adjusted for age sex and body mass index (BMI); †OR estimates are adjusted for age, sex, BMI and Kellgren--Lawrence grade; ‡OR estimates are adjusted for relatedness between twins. COS, Clearwater Osteoarthritis Study; GOAL, Genetics of Osteoarthritis and Lifestyle; HCS, Hertfordshire Cohort Study; TASOAC, Tasmanian Older Adult Cohort.](ard-70-9-1556-fig1){#F1}

We also investigated whether there was a difference between asymptomatic and symptomatic knee OA cases adjusting for age, sex, BMI and radiographic severity and this difference achieved statistical significance ([figure 1D](#F1){ref-type="fig"}) (OR=0.74, 95% CI 0.57 to 0.97 p=0.014).

Gene expression {#s8}
---------------

Gavenis *et al* demonstrated that *TRPV1* is expressed in articular chondrocytes, but expression decreases with dedifferentiation of the cells upon in vitro culture and passaging.[@R12] Here we evaluated the effects of the proinflammatory and cartilage destructive cytokines IL-1 and TNFα on gene expression of *TRPV1* in articular cartilage explants obtained from patients with end-stage knee OA, undergoing prosthesis surgery. Exposure to IL-1 and TNFα in vitro significantly upregulated *TRPV1* expression in challenged cartilage (average relative expression 3.34 (95% CI 2.55 to 4.37) versus 1 (95% CI 0.68 to 1.48) (n=4) ([figure 2A](#F2){ref-type="fig"}). Expression of *TRPV1* in synovial fibroblasts from patients with rheumatoid arthritis and OA[@R14] and in the synoviocyte cell line SW982[@R20] has been shown to be upregulated by TNFα. Despite this, we found no difference in the expression of *TRPV1* in synovial tissue biopsy specimens between patients without, and those with, inflammatory arthritis, suggesting that proinflammatory cytokines have differential effects on synovial tissue and articular cartilage (average relative expression compared with β-actin (×1000) 2.48 (95% CI −1.80 to 6.00)) versus 3.47 (95% CI −1.37 to 8.29)) (n=3 per group) ([figure 2B](#F2){ref-type="fig"}). Given the difference between our observations in articular cartilage and synovial tissue, we further examined the regulation of *TRPV1* expression in normal human synovial fibroblast in the presence or absence of IL-1 and TNFα. In contrast to the results reported for SW982 cells, we found no upregulation or downregulation of *TRPV1* in synovial fibroblasts treated with IL-1 or TNFα for 30 min to 24 h (dose range 0.1--10 ng/ml (n=3) (data not shown).

![Gene expression of *TRPV1* in joint tissues. (A) Cartilage explants from knee prosthesis surgery patients (n=4) were cultured in Dulbecco\'s modified Eagle\'s medium/10% fetal bovine serum for 10 days with or without tumour necrosis factor α (TNFα) and interleukin 1 (IL-1; 10 ng/ml) (triplicates). *TRPV1* expression was determined by real-time quantitative PCR and analysed using the delta-delta Ct method standardised for independent biological replicates. Data are expressed as mean and 95% CIs. The difference between the control conditions and the cytokine cultured conditions yielded a p\<0.0001 in a Mann--Whitney U test. (B) Synovial biopsy specimens were analysed for expression of *TRPV1* by real-time qualitative PCR and data expressed as mean and 95% CIs using relative expression compared with housekeeping gene β-actin (n=3). The difference between the control conditions and the cytokine cultured conditions yielded a p\<0.0.4 in a Mann--Whitney U test.](ard-70-9-1556-fig2){#F2}

Discussion {#s9}
==========

In this study we report for the first time an association between the *TRPV1* gene and risk of symptomatic knee OA. We found a significant association between an amino acid variant in the TRPV1 molecule, which previously had been implicated in pain sensitivity, with the risk of symptomatic but not asymptomatic radiographic knee OA. The observation that the genotype implicated in lower pain sensitivity is significantly associated with a lower risk of painful OA agrees with our initial hypothesis. After adjustment for confounding variables (age, sex, BMI and radiographic severity) the difference between symptomatic and asymptomatic OA also achieves statistical significance, further supporting our initial hypothesis.

We note that there are some study limitations. We only investigated the role of a single variant in the *TRPV1* gene and other SNPs in *TRPV1* may show a stronger association, which may be identified by finer mapping of this gene. Moreover, our data apply only to subjects of European descent. Differences in the strength or even the presence of genetic associations have been reported between Asian and European patients (eg, Valdes *et al*[@R21]), therefore it is possible that this variant may not be associated in other ethnic groups.

It is well recognised that there is an important genetic contribution to the development of OA, with heritability estimates in the order of 40--60% for knee, hip and hand OA.[@R22] However, most studies investigating genetic associations with OA have focused on structural change in joint tissues rather than the clinical presentation with pain and disability once OA changes are established. Our finding that the association with the *TRPV1* gene is significant only with symptomatic OA suggests that consideration of the pain component of OA may aid discovery of stronger or more consistent genetic associations with OA.

Patients seek medical help for symptoms and the main indication for knee arthroplasty, the most effective treatment for severe knee OA, is pain rather than the degree of structural ROA. It is therefore essential to understand the relationship between radiographic changes and pain in OA. Although there is a statistically significant association between knee ROA and pain, it has been reported that \<56% of subjects with moderate to severe knee ROA (K/L≥3) actually experience regular pain.[@R2]--[@R5] A US study analysed patients with frequent pain in only one knee, but who had bilateral radiographs and found that although increasing radiographic severity was significantly associated with knee pain, 46% of participants had the same radiographic grade in the symptomatic and asymptomatic knee and 10% had a worse radiographic grade in the asymptomatic knee.[@R23] Recently it has been shown that OA patients with high pre-arthroplasty pain and a low pain thresholds have higher persistent pain post-TKR for OA, reflecting the importance of an inherent predisposition to higher pain sensitivity.[@R24] Genetic variation is one of the factors that can help explain the prevalence of pain in OA and this study adds new data in this direction. Understanding the molecular determinants of pain in knee OA has important clinical implications because current non-surgical treatments for knee OA offer limited pain relief with effect sizes of \<0.5 for the most commonly used oral treatments when analysed in high-quality trials.[@R25] New insights into the aetiopathogenesis of pain in patients with knee ROA may produce novel targets for new therapeutic interventions.

The genetic findings reported in this paper are supported by preclinical studies, which indicate an important role of *TRPV1* in pain processing and, specifically, in experimental models of OA pain (see 'Introduction'). Indeed, *TRPV1* expression by the primary afferent sensory fibre cell bodies innervating the joint is upregulated in a model of OA.[@R10] This altered expression of *TRPV1* is likely to have an impact upon both peripheral and spinal[@R26] pain mechanisms in these models of OA pain. Since *TRPV1* is expressed not only by primary afferent fibres, but also in joint tissues, it is possible that the genetic variation in the *TRPV1* gene may influence structural damage associated with OA. This notion is supported by evidence for a contribution of primary afferent nociceptors to the progression of structural changes within the joint. In that study, degeneration of primary afferent nociceptors innervating the joint after intra-articular injection of capsaicin significantly decreased loss of bone volume and trabecular connectivity in a model of OA pain.[@R27] Such data suggest that primary afferent nociceptors innervating the joint may also contribute to the progression of structural damage. Thus, in animal models of OA *TRPV1* has complex contributions to the structural changes and pain associated with OA, which may reflect the multiple sites at which *TRPV1* is expressed within the joint and the pain pathways.

Our gene expression data in humans demonstrate that cytokine-induced stress to the articular cartilage increases expression of *TRPV1*. Interestingly, TNFα influences the phenotype and responses of primary afferent nociceptors---for example, TNFα increases the proportion of neurons that express *TRPV1*,[@R28] and therefore contributes to the generation and maintenance of inflammatory joint pain. On this basis, *TRPV1* may influence both peripheral pain sensitivity and structural damage in knee OA. This is in agreement with recent clinical studies showing that the presence of knee pain is an independent predictor of longitudinal cartilage loss in patients with OA in addition to radiographic severity.[@R29]

On the other hand, we failed to observe any differences between expression of *TRPV1* in normal and chronic inflammatory arthritis synovium. Earlier reports have demonstrated the expression of *TRPV1* in synovial fibroblasts. We could not confirm upregulation by TNFα or IL-1 in our experimental system as was reported for a synovial cell line. However, in this cell line Kochucov *et al* also reported increased thermal and chemical responses of TRPV channels in response to TNFα.[@R20] In addition, Hu and coworkers associated *TRPV1* with cell death in rat synoviocytes.[@R30] Of note, the synovial samples used in our experiements were not of OA origin and further research in OA synovium is needed to confirm or disprove this lack of response to cytokines. Given that the cell bodies of the afferent fibres are in the dorsal root ganglia and that cartilage is not normally innervated, the altered expression in the chondrocytes would appear to suggest a role for *TRPV1* in structural damage in OA. Further experiments investigating the role of *TRPV1* in pain in OA and in joint damage in OA will help clarify this issue.

*TRPV1*, a member of the extended family of non-selective cationic TRP channels, is important in pain sensation. At the time of writing there are compounds approved, or under consideration, for regulatory approval which target this receptor to treat pain in large-joint OA.[@R31] Our data suggest that a study of genetic factors that specifically influence the risk of symptomatic OA may point to therapeutic pathways for the treatment of OA.
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